Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP5 | P51878 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10819405 | 0.90 | CHKA (0.57) | CHKAALDH1A1KDM4EMAPTCYP2D6 | |
| SCHEMBL12426565 | 0.88 | ALDH1A1 (0.51) | ALDH1A1KDM4EMAPTCYP2D6CYP3A4 | |
| SCHEMBL24565989 | 0.87 | ALDH1A1 (0.54) | CHKAALDH1A1KDM4ECYP2D6CYP3A4 | |
| SCHEMBL10104420 | 0.87 | ALDH1A1 (0.58) | CHKAALDH1A1KDM4ECYP2D6CYP3A4 | |
| SCHEMBL18775237 | 0.86 | ALDH1A1 (0.58) | CHKAALDH1A1KDM4EMAPTMC4R | |
| SCHEMBL13960087 | 0.86 | ALDH1A1 (0.60) | CHKAALDH1A1KDM4ECYP2D6CYP3A4 | |
| SCHEMBL6925369 | 0.84 | CHKA (0.52) | CHKAALDH1A1KDM4EMAPTCYP2D6 | |
| SCHEMBL7812427 | 0.84 | CHKA (0.68) | CHKAALDH1A1KDM4EMAPTCYP2D6 | |
| SCHEMBL18783072 | 0.84 | ALDH1A1 (0.56) | CHKAALDH1A1KDM4EMAPTCYP2D6 | |
| SCHEMBL21974946 | 0.84 | CHKA (0.49) | CHKAALDH1A1KDM4EMAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022212326-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-10946021-B2 | Methods of treating or alleviating joint diseases by administering an inhibitor of discoidin domain receptor 1 (DDR1) | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-03-16 | — | — | US | disclosed |
| WO-2020079652-A1 | KINASE INHIBITORS | Insilico Medicine Hong Kong Limited (CN) | 2020-04-23 | — | — | WO | disclosed |
| US-20200030332-A1 | INHIBITOR AND ACTIVATOR OF DISCOIDIN DOMAIN RECEPTOR 1 AND THEIR USE | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2020-01-30 | — | — | US | disclosed |
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| US-9493455-B2 | Azaindole derivatives as inhibitors of protein kinases | ORIBASE PHARMA (FR) | 2016-11-15 | — | — | US | disclosed |
| US-9493455-B2 | Azaindole derivatives as inhibitors of protein kinases | ORIBASE PHARMA (FR) | 2016-11-15 | — | — | US | disclosed |
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1562933-B1 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | AMGEN INC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946021-B2 | Methods of treating or alleviating joint diseases by administering an inhibitor of discoidin domain receptor 1 (DDR1) | DDR1, DDR2, DDRGK1 | CHKA 3450/4885ALDH1A1 2824/4885KDM4E 3633/4885 |
| US-20200030332-A1 | INHIBITOR AND ACTIVATOR OF DISCOIDIN DOMAIN RECEPTOR 1 AND THEIR USE | DDR1, DDR2, DDRGK1 | CHKA 2968/4885ALDH1A1 3691/4885KDM4E 3540/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | CHKA 857/4885ALDH1A1 327/4885KDM4E 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.